Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NanoViricides Logo
NanoViricides Growth Score
64
CB Rank
20619
Heat Score
86
NanoViricides is a nano-biopharmaceutical company that develops therapeutics for patients suffering from life-threatening viral infections.
Founded
obfuscation
PublicPost-IPO Equity West Haven, Connecticut, United States1-10 www.nanoviricides.com
Biopharma
Biotechnology
Medical
Overview

NanoViricides
Total Funding
obfuscation
Growth Score
64
Heat Score
86

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score64
-15 pts
in past quarter
Heat Score 86
25 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About NanoViricides

CB Rank
20619
NanoViricides is a nano-biopharmaceutical company that develops therapeutics for patients suffering from life-threatening viral infections.
Founded
obfuscation
PublicPost-IPO Equity West Haven, Connecticut, United States1-10 www.nanoviricides.com
Biopharma
Biotechnology
Medical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Randall W. Barton
    Randall W. Barton: Chief Scientific Officer
    Past Role: A&G Pharmaceutical, Vice-President of Drug Discovery
  • Photo of Meeta R. Vyas
    Meeta R. Vyas: Interim Chief Financial Officer
    Past Role: National Audubon Society (USA), Vice President

Details

Legal Name NANOVIRICIDES INC.
Operating Status Active
Stock Symbol  NASDAQ:NNVC
Company Type For Profit
Founders  Anil R. Diwan
About the Company
NanoViricides, is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
Phone Number +1-203-937-6137
Contact Email info@nanoviricides.com
Predictions & Insights

Growth Insight

See this Growth Insight
NanoViricides is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

NV-387
A broad-spectrum nanoviricide designed to target viruses such as RSV, COVID-19, Influenza, Bird Flu, Smallpox, and Monkeypox by binding and dismantling virus particles.
NV-HHV-1
A nanoviricide targeting viruses in the Herpes family, including shingles, by binding to and dismantling the virus particles.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NanoViricides Logo
Post-IPO Equity - NanoViricides
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of Milton Boniuk
Milton Boniuk
—
Post-IPO Debt - NanoViricides Logo
Post-IPO Debt - NanoViricides
—
Photo of Milton Boniuk
Milton Boniuk
—
Post-IPO Debt - NanoViricides Logo
Post-IPO Debt - NanoViricides
—
Photo of Milton Boniuk
Milton Boniuk
—
Post-IPO Debt - NanoViricides Logo
Post-IPO Debt - NanoViricides
—
Photo of Milton Boniuk
Milton Boniuk
—
Post-IPO Debt - NanoViricides Logo
Post-IPO Debt - NanoViricides
—
Photo of Milton Boniuk
Milton Boniuk
—
Post-IPO Debt - NanoViricides Logo
Post-IPO Debt - NanoViricides
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 7 Board Members and Advisors 1 Contacts 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

331
19.93%
 in past month

IT Spend

$212.7KThis year, NanoViricides is projected to spend $212.7K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Fortune Logo
Fortune
78
LinkedIn Logo
LinkedIn
68
Aspen Ideas Festival Logo
Aspen Ideas Festival
67

Actively Used Products

8NanoViricides uses 8 technology products and services including HTML5, Lightbox, and  Comodo PositiveSSL Certificates, according to G2 Stack.

Active Website Tech Count

5NanoViricides is actively using 5 technologies for its website, according to BuiltWith. These include DNSSEC, CommonCrawl Top 5m, and  Java EE.
Sub-Organizations
Frequently Asked Questions

Where is NanoViricides's headquarters? NanoViricides is located in West Haven, Connecticut, United States.Who invested in NanoViricides? NanoViricides has 2 investors including Milton Boniuk and  Seaside 88.When was the last funding round for NanoViricides? NanoViricides closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are NanoViricides's competitors? Alternatives and possible competitors to NanoViricides may include 60 Degrees Pharma, Model Medicines, and  Aligos Therapeutics.How much funding has NanoViricides raised to date? NanoViricides has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|